Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
作者信息
Gill Saar, Shapiro Jeremy, Westerman David, Prince H Miles
机构信息
Department of Oncology, Cabrini Medical Centre, Malvern, Australia.
出版信息
J Clin Oncol. 2007 Oct 1;25(28):4493-4. doi: 10.1200/JCO.2007.12.9338.
PMID:17906211
Abstract
摘要
相似文献
1
Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
J Clin Oncol. 2007 Oct 1;25(28):4493-4. doi: 10.1200/JCO.2007.12.9338.
2
[Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Ann Dermatol Venereol. 1995;122(10):663-6.
3
[Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
Pathol Biol (Paris). 1990 Oct;38(8):876-80.
4
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
J Clin Oncol. 2004 Mar 15;22(6):1118-25. doi: 10.1200/JCO.2004.04.165.
5
Neurological toxicity during metastatic melanoma treatment with fotemustine.
Melanoma Res. 2005 Dec;15(6):563-4. doi: 10.1097/00008390-200512000-00014.
6
Fotemustine in the treatment of brain primary tumors and metastases.
Cancer Invest. 1994;12(4):414-20. doi: 10.3109/07357909409038234.
7
Fotemustine for the treatment of melanoma.
Expert Opin Pharmacother. 2011 Dec;12(18):2891-904. doi: 10.1517/14656566.2011.633513. Epub 2011 Nov 14.
8
[Contribution of a new nitrosourea compound: fotemustine].
Pathol Biol (Paris). 1992 Dec;40(9 Pt 2):964-8.
9
Complete remission seven years after treatment for metastatic malignant melanoma.
Cancer. 1996 Mar 1;77(5):900-2.
10
Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.
Eur J Haematol. 2009 Mar;82(3):240-1. doi: 10.1111/j.1600-0609.2008.01184.x. Epub 2008 Nov 10.
Zotero 插件